Phaseline

Targets › TNFSF4

TNFSF4 (Tumor necrosis factor ligand superfamily member 4): drug programs, companies and trials

3 programs from 3 companies in 59 trials: 20 Phase 2, 19 Phase 3, 13 Phase 1, 7 Phase 4; Immunology, Neurology, Gastroenterology; next expected readout Nov 2026.

Cytokine that binds to TNFRSF4. Co-stimulates T-cell proliferation and cytokine production. (UniProt, P23510)

Open in Phaseline: the race on TNFSF4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SanofiH5 Flu IMP 1
Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor
ROCK2, ROCK1, TNFSF4, CD38, IL4RPhase 4RSV Immunization; Diabetes Mellitus, Type 1; Asthma; Dermatitis Atopic …Dec 2026
Scleroderma Research Foundation, Inc.Amlitelimab
Tumor necrosis factor ligand superfamily member 4 inhibitor
TNFSF4Phase 2Interstitial Lung Disease Due to Systemic DiseaseNov 2026
Oxion BiologicsOX118
human monoclonal antibody targeting OX40 ligand (OX40L)
TNFSF4Phase 1Immune System–

Conditions

Dermatitis Atopic (5) Colitis Ulcerative (4) Chronic Graft Versus Host Disease (3) Crohn's Disease (3) Plasma Cell Myeloma Refractory (3) Asthma (2) Hemophilia (2) Plasma Cell Myeloma (2) Ulcerative Colitis (2) Type 1 Diabetes Mellitus (2) Healthy Volunteers (2) RSV Immunization (1)

Modalities

protein or peptide (1), mixed (1)

Companies

Sanofi (1) Scleroderma Research Foundation, Inc. (1) Oxion Biologics (1)

Related targets

ROCK2 (1) ROCK1 (1) CD38 (1) IL4R (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.